全文获取类型
收费全文 | 6861篇 |
免费 | 407篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 97篇 |
儿科学 | 128篇 |
妇产科学 | 143篇 |
基础医学 | 706篇 |
口腔科学 | 192篇 |
临床医学 | 588篇 |
内科学 | 1955篇 |
皮肤病学 | 66篇 |
神经病学 | 773篇 |
特种医学 | 296篇 |
外科学 | 1166篇 |
综合类 | 6篇 |
预防医学 | 242篇 |
眼科学 | 55篇 |
药学 | 375篇 |
中国医学 | 12篇 |
肿瘤学 | 546篇 |
出版年
2024年 | 14篇 |
2023年 | 105篇 |
2022年 | 190篇 |
2021年 | 312篇 |
2020年 | 229篇 |
2019年 | 246篇 |
2018年 | 271篇 |
2017年 | 176篇 |
2016年 | 235篇 |
2015年 | 261篇 |
2014年 | 311篇 |
2013年 | 405篇 |
2012年 | 568篇 |
2011年 | 529篇 |
2010年 | 290篇 |
2009年 | 264篇 |
2008年 | 363篇 |
2007年 | 395篇 |
2006年 | 322篇 |
2005年 | 311篇 |
2004年 | 314篇 |
2003年 | 266篇 |
2002年 | 210篇 |
2001年 | 105篇 |
2000年 | 69篇 |
1999年 | 81篇 |
1998年 | 56篇 |
1997年 | 44篇 |
1996年 | 35篇 |
1995年 | 35篇 |
1994年 | 29篇 |
1993年 | 20篇 |
1992年 | 37篇 |
1991年 | 31篇 |
1990年 | 29篇 |
1989年 | 20篇 |
1988年 | 15篇 |
1987年 | 17篇 |
1986年 | 15篇 |
1985年 | 17篇 |
1984年 | 15篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1979年 | 16篇 |
1978年 | 11篇 |
1973年 | 7篇 |
1972年 | 3篇 |
1969年 | 4篇 |
排序方式: 共有7346条查询结果,搜索用时 31 毫秒
91.
The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). 总被引:5,自引:0,他引:5
H Hasle I Baumann E Bergstr?sser S Fenu A Fischer G Kardos G Kerndrup F Locatelli T Rogge K R Schultz J Stary M Trebo M M van den Heuvel-Eibrink J Harbott P N?llke C M Niemeyer 《Leukemia》2004,18(12):2008-2014
The International Prognostic Scoring System (IPSS) for myelodysplastic syndrome (MDS) is based upon weighted data on bone marrow (BM) blast percentage, cytopenia, and cytogenetics, separating patients into four prognostic groups. We analyzed the value of the IPSS in 142 children with de novo MDS and 166 children with juvenile myelomonocytic leukemia (JMML) enrolled in retro- and prospective studies of the European Working Group on childhood MDS (EWOG-MDS). Survivals in MDS and JMML were analyzed separately. Among the criteria considered by the IPSS score, only BM blasts <5% and platelets >100 x 10(9)/l were significantly associated with a superior survival in MDS. In JMML, better survival was associated with platelets >40 x 10(9)/l, but not with any other IPSS factors including cytogenetics. In conclusion, the IPSS is of limited value in both pediatric MDS and JMML. The results reflect the differences between myelodysplastic and myeloproliferative diseases in children and adults. 相似文献
92.
P Comoli R De Palma S Siena A Nocera S Basso F Del Galdo R Schiavo O Carminati A Tagliamacco G F Abbate F Locatelli R Maccario P Pedrazzoli 《Annals of oncology》2004,15(1):113-117
BACKGROUND: The outcome of patients with nasopharyngeal carcinoma (NPC) presenting as advanced-stage disease or failing conventional radio-chemotherapy is poor. Thus, additional forms of effective, low-toxicity treatment are warranted to improve NPC prognosis. Since NPC is almost universally associated with Epstein-Barr virus (EBV), cellular immunotherapy with EBV-specific cytotoxic T lymphocytes (CTLs) may prove a successful treatment strategy. Patient and methods A patient with relapsed NPC, refractory to conventional treatments, received salvage adoptive immunotherapy with EBV-specific CTLs reactivated ex vivo from a human leukocyte antigen-identical sibling. EBV-specific immunity, as well as T-cell repertoire in the tumor, before and after immunotherapy, was evaluated. RESULTS: CTL transfer was well tolerated, and a temporary stabilization of disease was obtained. Moreover, notwithstanding the short in-vivo duration of allogeneic CTLs, immunotherapy induced a marked increase of endogenous tumor-infiltrating CD8+ T lymphocytes, and a long-term increase of latent membrane protein 2-specific immunity. CONCLUSIONS: Preliminary data obtained in this patient indicate that EBV-specific CTLs are safe, may exert specific killing of NPC tumor cells in vitro, and induce antitumor effect in vivo. 相似文献
93.
G. Schaison O. B. Eden G. Henze W. A. Kamps F. Locatelli J. Ninane J. Ortega P. Riikonen H. P. Wagner 《European journal of pediatrics》1998,157(12):955-966
During 1996 and 1997 a panel of European haematologists, oncologists, and neonatologists developed specific paediatric guidelines
for the use of colony stimulating factors based on published literature and the clinical experience of these specialists within
each of 13 countries. Well established indications for use comprise intervention in patients with life-threatening infection,
adjunctive therapy post autologous bone marrow transplantation (BMT), mobilization of peripheral blood progenitor cells for
autologous BMT, patients with acquired aplastic anaemia on anti-lymphocyte globulin and cyclosporin regimen, and severe congenital
neutropenia. Less clear indications include primary prophylaxis to support dose intensification in children with high risk/advanced
malignancies, secondary prophylaxis to prevent neutropenia in patients with a history of severe neutropenia, support therapy
in cases of poor marrow function following BMT and for deteriorating marrow function following successful BMT, in neonatal
sepsis and non infectious neonatal neutropenia, in drug induced neutropenia and in HIV-positive patients. Treatment is generally
well tolerated and granulocyte colony stimulating factor appears better tolerated than granulocyte and macrophage colony stimulating
factor. Economically colony stimulating factors have not been shown to induce excessive costs for a given patient.
Conclusion In general the adult guidelines are applicable to children but additional considerations (aggressive or very progressive
childhood neoplasms, specific indications, neonatal use, congenital disorders) must be taken into account.
Received: 21 October 1997 and in revised form: 30 April 1998 /Accepted: 5 May 1998 相似文献
94.
Davide Serrano Laura Baglietto Harriet Johansson Frederique Mariette Rosalba Torrisi Marina Onetto Michela Paganuzzi Andrea Decensi 《Clinical cancer research》2005,11(5):2083-2088
PURPOSE: Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models. EXPERIMENTAL DESIGN: We measured the changes in total and free prostate-specific antigen (PSA) and its association with insulin-like growth factor I (IGF-I) and IGFBP-3 levels after 1 year of treatment in 24 subjects given 4-HPR and 24 control subjects enrolled in a randomized bladder cancer prevention trial. RESULTS: No significant effect of 4-HPR was observed on total and free fraction of PSA levels. The median percentage [95 confidence interval (95% CI)] change for % free PSA and total PSA in the 4-HPR and the control group were, respectively, 7.6 (95% CI, -4.0 to 69.3) versus 5.1 (95% CI, -21.4 to 59.8) and -7.8 (95% CI, -18.2 to 52.5) versus -12.3 (95% CI, -44.6 to 9.6). However, in patients ages <60 years, there was a trend to an increase of total free PSA and % free PSA after treatment with 4-HPR that was different from a trend to a decrease in the control group (P = 0.002 and 0.052, respectively). The interaction between age and treatment was statistically significant on free PSA (P = 0.001). A similar pattern was noted with smoking status (P = 0.011 for the interaction on free PSA). No association was observed between PSA levels and IGF-I or IGFBP-3 levels. CONCLUSIONS: We conclude that 4-HPR has no significant effect on circulating PSA, but it increases significantly free PSA levels in subjects younger than 60 years and in nonsmokers. These effects might support an activity in prostate cancer prevention but further studies are required. 相似文献
95.
Melina Verso Giancarlo Agnelli Sergio Bertoglio Franco C Di Somma Francesco Paoletti Walter Ageno Mario Bazzan Pasquale Parise Roberto Quintavalla Emanuele Naglieri Armando Santoro Davide Imberti Mariella Sorarù Stefano Mosca 《Journal of clinical oncology》2005,23(18):4057-4062
PURPOSE: The extent of venous thromboembolism (VTE) associated with central vein catheters (CVC) in cancer patients remains unclear. The aim of this study was to evaluate the efficacy and safety of the low molecular weight heparin, enoxaparin, in the prevention of VTE. PATIENTS AND METHODS: In a multicenter, double-blind study, consecutive cancer patients scheduled for CVC insertion were randomly assigned to receive either subcutaneous enoxaparin 40 mg once a day or placebo. Treatment was started 2 hours before CVC insertion and continued for 6 weeks. The primary end points of the study were deep vein thrombosis (DVT), confirmed by venography of the CVC limb performed 6 weeks after randomization, or clinically overt pulmonary embolism, confirmed by objective testing during the study drug administration. Patients were assessed for bleeding complications. RESULTS: Three hundred eighty-five patients were randomized, of which 321 (83.4%) underwent venography. A venography was adequate for adjudication in 155 patients in each treatment group. A DVT was observed in 22 patients (14.1%) treated with enoxaparin and in 28 patients (18.0%) treated with placebo, corresponding to a relative risk of 0.78 (95% CI, 0.47 to 1.31). No major bleeding occurred. Five patients (2.6%) in the enoxaparin group and two patients (1.0%) in the placebo group died during the treatment period. CONCLUSION: In this study, no difference in the rate of CVC-related VTE was detected between patients receiving enoxaparin and patients receiving placebo. The dose of enoxaparin used in this study proved to be safe. Clinical trials evaluating higher enoxaparin doses could optimize the efficacy of this agent for this indication. 相似文献
96.
Alessio Nencioni Lucia Wille Giovanna Dal Bello Davide Boy Gabriella Cirmena Sebastian Wesselborg Claus Belka Peter Brossart Franco Patrone Alberto Ballestrero 《Clinical cancer research》2005,11(11):4259-4265
PURPOSE: Bcl-2 overexpression is frequently detected in lymphoid malignancies, being associated with poor prognosis and reduced response to therapy. Here, we evaluated whether Bcl-2 overexpression affects the cytotoxic activity of proteasome inhibitors taken alone or in association with conventional anticancer drugs or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). EXPERIMENTAL DESIGN: Jurkat cells engineered to overexpress Bcl-2 were treated with proteasome inhibitors (MG132, epoxomicin, and bortezomib), anticancer drugs (etoposide and doxorubicin), TRAIL, or combinations of these compounds. Cell death and loss of mitochondrial transmembrane potential were detected by flow cytometry. Cytosolic relocalization of cytochrome c and SMAC/Diablo, caspase cleavage, and Bcl-2 and Mcl-1 levels were determined by immunoblotting. Nuclear factor-kappaB inhibition was done by retroviral transduction with a dominant-negative mutant of IkappaBalpha. RESULTS: Bcl-2 overexpression results in significant inhibition of apoptosis in response to proteasome inhibitors, antiblastics, and TRAIL. Addition of TRAIL to proteasome inhibitors results in a synergistic cytotoxic effect in Bcl-2-overexpressing cells, whereas this result is not reproduced by the combination of proteasome inhibitors with antiblastic drugs. Importantly, proteasome inhibitors plus TRAIL induce mitochondrial dysfunction irrespective of up-regulated Bcl-2. Bcl-2 cleavage to a fragment with putative proapoptotic activity and elimination of antiapoptotic Mcl-1 may both play a role in proteasome inhibitors-TRAIL cooperation. Conversely, nuclear factor-kappaB inhibition by proteasome inhibitors is per se insufficient to explain the observed synergy. CONCLUSIONS: Combined proteasome inhibitors and TRAIL overcome the apoptotic threshold raised by Bcl-2 and may prove useful in the treatment of chemoresistant malignancies with up-regulated Bcl-2. 相似文献
97.
Andrea Pession Maria Grazia Valsecchi Giuseppe Masera Willem A Kamps Edina Magyarosy Carmelo Rizzari Elisabeth R van Wering Luca Lo Nigro Anna van der Does Franco Locatelli Giuseppe Basso Maurizio Aricò 《Journal of clinical oncology》2005,23(28):7161-7167
PURPOSE: Between September 1991 and May 1997, within the International Berlin-Frankfurt-Muenster Study Group (I-BFM-SG), a randomized study was performed aimed at assessing the efficacy of prolonged use of high-dose l-asparaginase (HD-l-ASP) during continuation therapy in children with standard risk (SR) acute lymphoblastic leukemia (ALL), treated with a reduced BFM-type chemotherapy. PATIENTS AND METHODS: The Italian, Dutch, and Hungarian groups participated in this study denominated IDH-ALL-91, and 494 children were enrolled. Treatment consisted of a BFM-type modified backbone with omission of the IB part in induction and elimination of two doses of anthracyclines during reinduction in both arms at the beginning of continuation therapy. Patients were randomly assigned to receive (YES-ASP) or not (NO-ASP) 20 weekly HD-l-ASP (25,000 IU/m2). RESULTS: The event-free-survival and overall survival probabilities at 10 years for the entire group were 82.5% (1.8) and 90.3% (1.3), respectively. Of the 490 patients eligible for random assignment, 355 (72.4%) were randomly assigned (178 YES-ASP and 177 NO-ASP). After a median follow-up of 9 years, the probability of disease-free survival at 10 years was 87.5% (SE, 2.5) for YES-ASP arm versus 78.7% (SE, 3.3) for NO-ASP arm (P = .03). In multivariate analysis, NO-ASP arm (P = .03), male sex (P = .004), and age older than 10 years (P = .0003) had a significantly adverse impact on outcome. CONCLUSION: In this subset of patients, selected with criteria not including monitoring of minimal residual disease, application of extended HD-l-ASP may improve prognosis, compensating reduced leukemia control that results from adoption of a reduced-intensity BFM-backbone for treatment of children with SR ALL. 相似文献
98.
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. 总被引:4,自引:0,他引:4
Anja Henningsson Sharon Marsh Walter J Loos Mats O Karlsson Adam Garsa Klaus Mross Stephan Mielke Lucia Viganò Alberta Locatelli Jaap Verweij Alex Sparreboom Howard L McLeod 《Clinical cancer research》2005,11(22):8097-8104
PURPOSE: To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol). EXPERIMENTAL DESIGN: A cohort of 97 Caucasian patients with cancer (median age, 57 years) received paclitaxel as an i.v. infusion (dose range, 80-225 mg/m(2)). Genomic DNA was analyzed using PCR RFLP or using Pyrosequencing. Pharmacokinetic variables for unbound paclitaxel were estimated using nonlinear mixed effect modeling. The effects of genotypes on typical value of clearance were evaluated with the likelihood ratio test within NONMEM. In addition, relations between genotype and individual pharmacokinetic variable estimates were evaluated with one-way ANOVA. RESULTS: The allele frequencies for the CYP2C8*2, CYP2C8*3, CYP2C8*4, CYP3A4*3, CYP3A5*3C, and ABCB1 3435C>T variants were 0.7%, 9.2%, 2.1%, 0.5%, 93.2%, and 47.1%, respectively, and all were in Hardy-Weinberg equilibrium. The population typical value of clearance of unbound paclitaxel was 301 L/h (individual clearance range, 83.7-1055 L/h). The CYP2C8 or CYP3A4/5 genotypes were not statistically significantly associated with unbound clearance of paclitaxel. Likewise, no statistically significant association was observed between the ABCB1 3435C>T variant and any of the studied pharmacokinetic variables. CONCLUSIONS: This study indicates that the presently evaluated variant alleles in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes do not explain the substantial interindividual variability in paclitaxel pharmacokinetics. 相似文献
99.
100.
Pharmaceutical Research - Present (i) an infrared (IR)-based Process Analytical Technology (PAT) installed in a lab-scale freeze-dryer and (ii) a micro freeze-dryer (MicroFD®) as effective... 相似文献